Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
FRA:NKB2 vs IMVT, SYRE, IBRX: Profitability Rank Comparison
For the Biotechnology subindustry, TG Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics Profitability Rank vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
TG Therapeutics has the Profitability Rank of 4.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics (FRA:NKB2) has a Profitability Rank of 4 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on TG Therapeutics and its competitors. This is 100% above median its historical median of 2.00. Over the past decade, TG Therapeutics' Profitability Rank has ranged from 1.00 to 3.00.
Is TG Therapeutics' Profitability Rank too high?
TG Therapeutics' current Profitability Rank of 4 is 100% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 3.00. Overall, TG Therapeutics has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Profitability Rank compare to IMVT and SYRE?
TG Therapeutics' Profitability Rank of 4 can be compared against companies in the Biotechnology industry. Historically, TG Therapeutics' own Profitability Rank has ranged from 1.00 to 3.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Biotechnology company?
A good Profitability Rank depends on the Biotechnology industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Profitability Rank is 4, which is 100% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
TG Therapeutics (FRA:NKB2) has a current Profitability Rank of 4. The current Profitability Rank is 4, which is 100% above median its 10-year median of 2.00. TG Therapeutics' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Profitability Rank is 4 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
58GF Score
Get the complete analysis for FRA:NKB2
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
